In the second half of 2021, acquisitions increased significantly by 35% from the same period in 2020.
This marks an acceleration in growth from the 6.2% decrease in deals seen from the first six months of 2020 to the same period in 2021.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataDuring this time, the region that saw the biggest increase in the number of deals was North America.
From the second half of 2020 to the second half of 2021, the largest regional increase in deals was also seen in North America.
The region saw a 50% increase in deals.
During second half of 2021, acquisitions accounted for 4.1% of deals taking place in the sector. This represents an increase from the figure of 1.2% in second half of 2020.
GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.
The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.
By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.
The highest value acquisition that took place in 2021 (where the deal value was known) was the $12.3m acquisition of Vifor Pharma by CSL.
The database states that the rationale behind this deal was as follows: "The transaction will enable Vifor Pharma to leverage CSL's global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant."